Emergent BioSolutions appoints John D. Fowler, Jr. to board of directors effective March 1, 2026

Emergent BioSolutions Inc.

Fowler appointed as Class II director and will serve on the Audit and Finance Committee.
Receives initial RSU grant valued at $270,000 vesting in three equal annual installments.
Annual compensation: $70,000 cash retainer, $15,000 committee fee, $270,000 equity award (prorated first year).
Chairman Zsolt Harsanyi states Fowler's experience will support the company's ongoing turnaround and transformation.
Fowler brings 30+ years in healthcare and finance, including senior roles at Wells Fargo, Deutsche Bank, and JPMorgan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.